Search Results - "L. Licitra"

Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Machiels, J-P, René Leemans, C, Golusinski, W, Grau, C, Licitra, L, Gregoire, V

Get full text

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up by Bossi, P., Chan, A.T., Licitra, L., Trama, A., Orlandi, E., Hui, E.P., Halámková, J., Mattheis, S., Baujat, B., Hardillo, J., Smeele, L., van Herpen, C., Castro, A., Machiels, J.-P.

“…•This ESMO-EURACAN Clinical Practice Guideline provides key recommendations for managing nasopharyngeal cancer (NPC).•It covers screening, clinical and…”
Get full text

Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Grégoire, V., Lefebvre, J.-L., Licitra, L., Felip, E.

Get full text

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study by Ferris, R.L., Haddad, R., Even, C., Tahara, M., Dvorkin, M., Ciuleanu, T.E., Clement, P.M., Mesia, R., Kutukova, S., Zholudeva, L., Daste, A., Caballero-Daroqui, J., Keam, B., Vynnychenko, I., Lafond, C., Shetty, J., Mann, H., Fan, J., Wildsmith, S., Morsli, N., Fayette, J., Licitra, L.

“…Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head…”
Get full text

Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations by Mirabile, A, Airoldi, M, Ripamonti, C, Bolner, A, Murphy, B, Russi, E, Numico, G, Licitra, L, Bossi, P

“…Abstract Pain in head and neck cancer represents a major issue, before, during and after the oncological treatments. The most frequent cause of pain is…”
Get full text

SP-0613: Will personalised medicine approaches increase therapeutic options for salivary gland cancers? by Licitra, L

Get full text

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial by Basset-Séguin, N., Hauschild, A., Kunstfeld, R., Grob, J., Dréno, B., Mortier, L., Ascierto, P.A., Licitra, L., Dutriaux, C., Thomas, L., Meyer, N., Guillot, B., Dummer, R., Arenberger, P., Fife, K., Raimundo, A., Dika, E., Dimier, N., Fittipaldo, A., Xynos, I., Hansson, J.

“…The SafeTy Events in VIsmodEgib study (STEVIE, ClinicalTrials.gov, NCT01367665), assessed safety and efficacy of vismodegib—a first-in-class Hedgehog pathway…”
Get full text

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma by Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M.C., Niederle, B., Cohen, E.E.W., Wirth, L., Ali, H., Clary, D.O., Yaron, Y., Mangeshkar, M., Ball, D., Nelkin, B., Sherman, S.

“…Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant…”
Get full text

SP-011: Targeted Agents: Cetuximab and Beyond by Licitra, L

Get full text

Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial by Bossi, P., Lo Vullo, S., Guzzo, M., Mariani, L., Granata, R., Orlandi, E., Locati, L., Scaramellini, G., Fallai, C., Licitra, L.

“…Data on preoperative chemotherapy in resectable oral cavity cancer are conflicting. We present the long-term results of a randomized trial of induction…”
Get full text

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial by Vermorken, J.B., Psyrri, A., Mesía, R., Peyrade, F., Beier, F., de Blas, B., Celik, I., Licitra, L.

“…Tumor human papillomavirus (HPV) status is an important prognostic factor in locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN)…”
Get full text

Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma by van Boxtel, W., Locati, L.D., van Engen-van Grunsven, A.C.H., Bergamini, C., Jonker, M.A., Fiets, E., Cavalieri, S., Tooten, S., Bos, E., Quattrone, P., Verhaegh, G.W., Schalken, J.A., Licitra, L., van Herpen, C.M.L.

“…Salivary duct carcinoma (SDC), an aggressive subtype of salivary gland cancer, is androgen receptor (AR)–positive in 67–96% of cases. In patients with locally…”
Get full text

‘Rare cancers’: not all together in clinical studies by Casali, P.G., Licitra, L., Frezza, A.M., Trama, A.

Get full text

SP-0587 BIOLOGY AND TARGETING OF HPV by Licitra, L

Get full text

Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Chan, A T C, Grégoire, V, Lefebvre, J-L, Licitra, L, Hui, E P, Leung, S F, Felip, E

Get full text

Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up by Licitra, L., Felip, E.

Get full text

Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy by Lefebvre, J. L., Rolland, F., Tesselaar, M., Bardet, E., Leemans, C. R., Geoffrois, L., Hupperets, P., Barzan, L., de Raucourt, D., Chevalier, D., Licitra, L., Lunghi, F., Stupp, R., Lacombe, D., Bogaerts, J., Horiot, J. C., Bernier, J., Vermorken, J. B.

“…Background Both induction chemotherapy followed by irradiation and concurrent chemotherapy and radiotherapy have been reported as valuable alternatives to…”
Get full text

Management of Tyrosine Kinase Inhibitors (TKI) Side Effects in Differentiated and Medullary Thyroid Cancer Patients by Resteghini, C, Cavalieri, S, Galbiati, D, Granata, R, Alfieri, S, Bergamini, C, Bossi, P, Licitra, L, Locati, L.D

“…Abstract Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib…”
Get full text

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study by Licitra, L., Mesia, R., Rivera, F., Remenár, É., Hitt, R., Erfán, J., Rottey, S., Kawecki, A., Zabolotnyy, D., Benasso, M., Störkel, S., Senger, S., Stroh, C., Vermorken, J.B.

“…The phase III EXTREME study demonstrated that combining cetuximab with platinum/5-fluorouracil (5-FU) significantly improved overall survival in the first-line…”
Get full text

Reprint of “Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up” by Machiels, J.-P., René Leemans, C., Golusinski, W., Grau, C., Licitra, L., Gregoire, V.

“…•This EHNS-ESMO-ESTRO Clinical Practice Guideline provides key recommendations for managing SCCHN.•It covers clinical and pathological diagnosis, staging and…”
Get full text